Shopping Cart
- Remove All
- Your shopping cart is currently empty
LG100754 (UVI 2112) is an insulin sensitizer that functions through RXR. LG100754 is an RXR dimer modulator. LG100754 acts as an RXR: RXR homodimer antagonist, but functions as an agonist towards RXR: PPARα and RXR: PPARγ heterodimers.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
25 mg | $993 | 6-8 weeks | |
50 mg | $1,290 | 6-8 weeks | |
100 mg | $1,970 | 6-8 weeks |
Description | LG100754 (UVI 2112) is an insulin sensitizer that functions through RXR. LG100754 is an RXR dimer modulator. LG100754 acts as an RXR: RXR homodimer antagonist, but functions as an agonist towards RXR: PPARα and RXR: PPARγ heterodimers. |
In vitro | LG100754 functions as an activator of endogenous RXR heterodimers, specifically facilitating the activity of RXR: PPARγ heterodimers. It plays a crucial role in regulating insulin-dependent signaling pathways. Additionally, LG100754 has been shown to mitigate TNFα-mediated insulin resistance in mature adipocytes[1]. |
In vivo | LG100754 (100 mg/kg) fully blocks the enhance in glucose levels. It also shows that LG100754 can improve insulin resistance in vivo[1]. |
Alias | UVI 2112 |
Molecular Weight | 396.56 |
Formula | C26H36O3 |
Cas No. | 180713-37-5 |
Smiles | CCCOc1cc2c(cc1\C(C)=C/C=C/C(/C)=C/C(O)=O)C(C)(C)CCC2(C)C |
Relative Density. | 1.003g/cm3 |
Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
Solubility Information | DMSO: 90.0 mg/mL (227.0 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
|
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.